tert-butyl 4,4-dimethyl-1,2,3-oxathiazinane-3-carboxylate 2,2-dioxide | 521267-13-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机硫酸及其衍生物
• 英文名称: tert-butyl 4,4-dimethyl-1,2,3-oxathiazinane-3-carboxylate 2,2-dioxide
• 英文别名: tert-butyl-4,4-dimethyl-1,2,3-oxathiazinane-3-carboxylate-2,2-dioxide；4,4-dimethyl-2,2-dioxo(1,2,3)oxathiazinane-3-carboxylic acid tertbutyl ester；tert-butyl 4,4-dimethyl-2,2-dioxo-2-[1,2,3]oxathiazinan-3-carboxylate；N-tert-butoxycarbonyl-4,4-dimethyl-[1,2,3]oxathiazinane-2,2-dioxide；tert-butyl 4,4-dimethyl-2,2-dioxo-[1,2,3]oxathiazinan-3-carboxylate；N-tert-butoxycarbonyl-4,4-dimethyl-[1,2,3]oxathiazinan-2,2-dioxide；tert-butyl 4,4-dimethyl-2,2-dioxooxathiazinane-3-carboxylate
• CAS: 521267-13-0
• 化学式: C₁₀H₁₉NO₅S
• 分子量: 265.331
• InChiKey: QTUCVHJOZFLPQT-UHFFFAOYSA-N

物化性质

• 沸点：
  316.0±25.0 °C(Predicted)
• 密度：
  1.202±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  81.3
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl 4,4-dimethyl-1,2,3-oxathiazinane-3-carboxylate 2,2-dioxide 在 吡啶 、 甲烷磺酸 、 potassium tert-butylate 、 sodium carbonate 、 potassium carbonate 、 potassium hydroxide 作用下， 以 四氢呋喃 、 2-甲基-2-丁醇 、 二氯甲烷 、 水 、 乙腈 为溶剂， 反应 143.42h， 生成 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2 diphenyl hexanamide hydrochloride
  参考文献：
  名称：

  Development of a Scaleable Synthesis of a Geminal Dimethyl Tertiary Amine as an Inhaled Muscarinic Antagonist for the Treatment of COPD

  摘要：

  An efficient and scalable process for the synthesis of muscarinic antagonist, PF-3635659 1, is described, illustrating redesign of an analogue-targeted synthesis which contained a scale-limiting rhodium-activated C H amination step. The final route includes a reproducible modified Bouveault reaction which has not previously been reported on a substrate of this complexity, or on such a scale with over 5 kg of the requisite gem-dimethylamine prepared via this methodology.

  DOI：

  10.1021/op200233r
• 作为产物：
  描述：

  异戊醇 在 吡啶 、 4-二甲氨基吡啶 、 manganese(IV) oxide 、 dirhodium tetraacetate 、 甲酸 、 氯磺酰异氰酸酯 、 碘苯二乙酸 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 20.33h， 生成 tert-butyl 4,4-dimethyl-1,2,3-oxathiazinane-3-carboxylate 2,2-dioxide
  参考文献：
  名称：

  Development of a Scaleable Synthesis of a Geminal Dimethyl Tertiary Amine as an Inhaled Muscarinic Antagonist for the Treatment of COPD

  摘要：

  An efficient and scalable process for the synthesis of muscarinic antagonist, PF-3635659 1, is described, illustrating redesign of an analogue-targeted synthesis which contained a scale-limiting rhodium-activated C H amination step. The final route includes a reproducible modified Bouveault reaction which has not previously been reported on a substrate of this complexity, or on such a scale with over 5 kg of the requisite gem-dimethylamine prepared via this methodology.

  DOI：

  10.1021/op200233r

文献信息

• Indol-containing beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions
  申请人：Walter Rainer

  公开号：US20070105906A1

  公开（公告）日：2007-05-10

  The present invention relates to new beta-agonists of general formula (I) wherein the groups R 1 and R 2 have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers, solvates, hydrates, mixtures thereof, the prodrugs thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, methods of preparing these compounds and their use as pharmaceutical compositions.

  本发明涉及一般式（I）的新β-激动剂，其中基团R1和R2具有权利要求和说明中给定的含义，其互变异构体、消旋体、对映体、非对映体、溶剂合物、水合物、它们的混合物、它们的前药和它们的盐，特别是它们与无机或有机酸或碱的生理上可接受的盐，以及制备这些化合物的方法和它们作为药物组成物的用途。
• Novel Beta-Agonists, Process for Their Preparation and Their Use as Medicaments
  申请人：Walter Rainer

  公开号：US20080300290A1

  公开（公告）日：2008-12-04

  Compounds of general formula (I) which are selective beta-3-agonists and useful for the treatment of obesity and type II diabetes. Exemplary compounds are: [4-(1-3-[2-(3-phenylsulphonylamino-phenyl)-2-hydroxy-ethylamino]-3-methyl-butyl}-1H-imidazol-4-yl)-phenyl]-acetic acid and methyl [4-(1-3-[2-(3-phenylsulphonylamino-phenyl)-2-hydroxy-ethylamino]-3-methyl-butyl}-1H-imidazol-4-yl)-phenyl]-acetate.

  通式（I）的化合物是选择性β-3-激动剂，用于治疗肥胖和2型糖尿病。示例化合物包括：[4-(1-3-[2-(3-苯磺酰氨基苯基)-2-羟基乙基氨基]-3-甲基丁基}-1H-咪唑-4-基)-苯基]-乙酸和甲基[4-(1-3-[2-(3-苯磺酰氨基苯基)-2-羟基乙基氨基]-3-甲基丁基}-1H-咪唑-4-基)-苯基]-乙酸酯。
• Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions
  申请人：Trieselmann Thomas

  公开号：US20070112033A1

  公开（公告）日：2007-05-17

  The present invention relates to new beta-agonists of general formula (I) wherein the groups R 1 to R 4 have the meanings given in ths claims and specification, the tautomers, racemates, enantiomers, diastereomers, solvates, hydrates, mixtures thereof, the prodrugs thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, methods of preparing these compounds and their use as pharmaceutical compositions.

  本发明涉及一般式(I)的新β-激动剂，其中基团R1至R4具有权利要求和说明书中给定的含义，其互变异构体、外消旋体、对映体、非对映体、溶剂合物、水合物、它们的混合物，它们的前体药物及其盐，特别是其与无机或有机酸或碱的生理上可接受的盐，以及制备这些化合物的方法和它们作为药物组合物的用途。
• Carboxamide derivatives as muscarinic receptor antagonists
  申请人：Pfizer Inc.

  公开号：US07772223B2

  公开（公告）日：2010-08-10

  The invention relates to compounds of formula processes and intermediates for their preparation, their use as muscarinic antagonists and pharmaceutical composition containing them.

  本发明涉及化合物的公式，其制备过程和中间体，以及它们作为肌肉型乙酰胆碱受体拮抗剂的用途和包含它们的制药组合物。
• Carboxamide Derivatives As Muscarinic Receptor Antagonists
  申请人：Glossop Paul Alan

  公开号：US20100029720A1

  公开（公告）日：2010-02-04

  The invention relates to compounds of formula processes and intermediates for their preparation, their use as muscarinic antagonists and pharmaceutical composition containing them.

  本发明涉及具有以下式的化合物，以及制备它们的过程和中间体，它们作为毒蕈碱受体拮抗剂的用途和包含它们的制药组合物。